• Briacell Therapeutics expanded pipeline to ovarian cancer with Bria-OVA+, a personalized, off-the-shelf cell-based immunotherapy candidate under development for potential clinical use.
• No new clinical trial results were presented; announcement followed previously reported Phase 2 results in metastatic breast cancer described as encouraging on efficacy and tolerability.
• Program aims to deliver a differentiated immunotherapy option for ovarian cancer patients who do not respond to current treatments, a segment viewed as a key unmet need.
• Development work started with licensed ovarian cancer cell lines from ATCC to support manufacturing of Bria-OVA+ for potential future studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Briacell Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150730PRIMZONEFULLFEED9720897) on May 15, 2026, and is solely responsible for the information contained therein.